This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hall, D. E. Articles by Ross, B. D. Search for Related Content PubMed PubMed Citation Articles by Hall, D. E. Articles by Ross, B. D.

Therapeutic Efficacy of DTI-015 using Diffusion Magnetic Resonance Imaging as an Early Surrogate Marker

¹ Center for Molecular Imaging and Departments of ² Radiology, ³ Biological Chemistry, ⁴ Radiation Oncology, and ⁵ Biostatistics, University of Michigan, Ann Arbor, Michigan; and ⁶ Direct Therapeutics Inc., Redwood City, California

To investigate diffusion weighted magnetic resonance imaging as a quantitative surrogate marker for evaluating the therapy-induced cellular changes in an orthotopic experimental glioma model, tumors were treated with direct intratumoral administration of DTI-015, a solution of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in 100% EtOH. Intracerebral 9L tumors were induced in Fischer 344 rats, and three treatment groups were established: DTI-015, EtOH, and sham. Two groups of rats received intratumoral injection of either 67 mg/mL BCNU in EtOH or EtOH alone at 50% of the tumor volume up to a maximum of 30 µl under stereotactic guidance. Diffusion magnetic resonance images were acquired before treatment and after treatment at 1, 24, 48, and 72 hours and then 3 times per week thereafter. Tumor cell viability was examined using multislice diffusion weighted magnetic resonance imaging with diffusion weighted transverse magnetic resonance images and histogram plots of each tumor quantified over time. Control animals (EtOH- or sham-treated animals) showed mean apparent diffusion coefficients (ADCs) that remained essentially unchanged over the experimental time course. In contrast, rats treated with DTI-015 showed a significant increase in ADC relative to the pretreatment within 24 hours, which further increased over time, followed by a significant therapeutic response as evidenced by subsequent tumor volume shrinkage, development of a cystic region, and enhanced animal survival. Finally, not only were ADC measurements predictive of differences between treatment groups, but they also yielded spatial and temporal data regarding the efficacy of treatment within individual treated animals that could be used to guide subsequent therapy.

This article has been cited by other articles:

				Y. Cui, X.-P. Zhang, Y.-S. Sun, L. Tang, and L. Shen Apparent Diffusion Coefficient: Potential Imaging Biomarker for Prediction and Early Detection of Response to Chemotherapy in Hepatic Metastases Radiology, September 1, 2008; 248(3): 894 - 900. [Abstract] [Full Text] [PDF]

				J. Lazovic, M. C. Jensen, E. Ferkassian, B. Aguilar, A. Raubitschek, and R. E. Jacobs Imaging Immune Response In vivo: Cytolytic Action of Genetically Altered T Cells Directed to Glioblastoma Multiforme Clin. Cancer Res., June 15, 2008; 14(12): 3832 - 3839. [Abstract] [Full Text] [PDF]

				D. A. Hamstra, A. Rehemtulla, and B. D. Ross Diffusion Magnetic Resonance Imaging: A Biomarker for Treatment Response in Oncology J. Clin. Oncol., September 10, 2007; 25(26): 4104 - 4109. [Abstract] [Full Text] [PDF]

				P. McConville, D. Hambardzumyan, J. B. Moody, W. R. Leopold, A. R. Kreger, M. J. Woolliscroft, A. Rehemtulla, B. D. Ross, and E. C. Holland Magnetic Resonance Imaging Determination of Tumor Grade and Early Response to Temozolomide in a Genetically Engineered Mouse Model of Glioma Clin. Cancer Res., May 15, 2007; 13(10): 2897 - 2904. [Abstract] [Full Text] [PDF]

				C. Soussain, L. L. Muldoon, C. Varallyay, K. Jahnke, L. DePaula, and E. A. Neuwelt Characterization and Magnetic Resonance Imaging of a Rat Model of Human B-Cell Central Nervous System Lymphoma Clin. Cancer Res., April 15, 2007; 13(8): 2504 - 2511. [Abstract] [Full Text] [PDF]

				K. C. Lee, D. A. Hamstra, M. S. Bhojani, A. P. Khan, B. D. Ross, and A. Rehemtulla Noninvasive Molecular Imaging Sheds Light on the Synergy between 5-Fluorouracil and TRAIL/Apo2L for Cancer Therapy Clin. Cancer Res., March 15, 2007; 13(6): 1839 - 1846. [Abstract] [Full Text] [PDF]

				K. C. Lee, B. A. Moffat, A. F. Schott, R. Layman, S. Ellingworth, R. Juliar, A. P. Khan, M. Helvie, C. R. Meyer, T. L. Chenevert, et al. Prospective Early Response Imaging Biomarker for Neoadjuvant Breast Cancer Chemotherapy Clin. Cancer Res., January 15, 2007; 13(2): 443 - 450. [Abstract] [Full Text] [PDF]

				W. J. Bodell, A. P. Bodell, and D. D. Giannini Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol) Neuro-oncol, January 1, 2007; 9(1): 12 - 19. [Abstract] [Full Text] [PDF]

				K. C. Lee, D. E. Hall, B. A. Hoff, B. A. Moffat, S. Sharma, T. L. Chenevert, C. R. Meyer, W. R. Leopold, T. D. Johnson, R. V. Mazurchuk, et al. Dynamic Imaging of Emerging Resistance during Cancer Therapy. Cancer Res., May 1, 2006; 66(9): 4687 - 4692. [Abstract] [Full Text] [PDF]

				Y. Cao, P. C. Sundgren, C. I. Tsien, T. T. Chenevert, and L. Junck Physiologic and Metabolic Magnetic Resonance Imaging in Gliomas J. Clin. Oncol., March 10, 2006; 24(8): 1228 - 1235. [Abstract] [Full Text] [PDF]

				D. A. Hamstra, T. L. Chenevert, B. A. Moffat, T. D. Johnson, C. R. Meyer, S. K. Mukherji, D. J. Quint, S. S. Gebarski, X. Fan, C. I. Tsien, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma PNAS, November 15, 2005; 102(46): 16759 - 16764. [Abstract] [Full Text] [PDF]

				A S K Dzik-Jurasz Pelvic malignancy: integrating form and function Br. J. Radiol., October 1, 2005; 78(Special_Issue_2): S86 - S93. [Abstract] [Full Text] [PDF]